0 CHECKOUT

Research Update: Rating On Denmark-Based DONG A/S Cut To 'BBB+' And Removed From CreditWatch; Outlook Stable Jun 05

  • ID: 2026874
  • June 2005
  • Standard & Poors

FEATURED COMPANIES

  • DONG Energy A/S
  • DONG Energy Power A/S
  • ENERGI E2 A/S
  • Vattenfall AB
  • MORE

Abstract
On June 2, 2005, Standard & Poor's Ratings Services lowered its long-term corporate credit rating on Denmark-based gas and energy company DONG A/S to 'BBB+' from 'A-'. At the same time, Standard & Poor's removed the long-term rating from CreditWatch, where it was placed with negative implications on Feb. 9, 2005. Standard & Poor's affirmed its 'A-2' short-term corporate credit rating on DONG. The outlook is stable. The rating action follows yesterday's announcement of an agreement between DONG and Vattenfall AB (A-/Stable/A-2), by which Vattenfall acquires power and heat-generating assets in Elsam A/S and Energi E2 A/S in return for its 35% ownership stake in Elsam. The downgrade reflects Standard & Poor's view that DONG's short- to medium-term credit protection...

Companies mentioned in this report are:
- DONG Energy A/S
- Vattenfall AB
- DONG Energy Power A/S
- ENERGI E2 A/S

Action: Downgraded
Action: Outlook: Positive

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. READ MORE >

Note: Product cover images may vary from those shown

- DONG Energy A/S
- Vattenfall AB
- DONG Energy Power A/S
- ENERGI E2 A/S

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: This Credit Rating Report will be emailed to you.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.